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Cyclophilin A: a key player for human disease
P Nigro*,1, G Pompilio1 and MC Capogrossi2
Cyclophilin A (CyPA) is a ubiquitously distributed protein belonging to the immunophilin family. CyPA has peptidyl prolyl
cis-trans isomerase (PPIase) activity, which regulates protein folding and trafficking. Although CyPA was initially believed to
function primarily as an intracellular protein, recent studies have revealed that it can be secreted by cells in response to
inflammatory stimuli. Current research in animal models and humans has provided compelling evidences supporting the critical
function of CyPA in several human diseases. This review discusses recently available data about CyPA in cardiovascular
diseases, viral infections, neurodegeneration, cancer, rheumatoid arthritis, sepsis, asthma, periodontitis and aging. It is believed
that further elucidations of the role of CyPA will provide a better understanding of the molecular mechanisms underlying these
diseases and will help develop novel pharmacological therapies.
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Facts
 CyPA is a critical mediator for cardiovascular diseases.
 High CyPA expression correlates with poor outcome of
patients with inflammatory diseases.
 CyPA regulates the infection and replication of several
viruses affecting humans.
 CyPA is generally overexpressed in cancer and regulates
malignant transformation and metastasis.
 CyPA is a crucial mediator in Alzheimer disease and
amyotrophic lateral sclerosis.
 CyPA secretion increases during pro-inflammatory
diseases, such as rheumatoid arthritis, sepsis and
asthma.
 CyPA expression increases with aging.
Open Questions
 Deepen the mechanisms by which CyPA contributes to the
development of human diseases.
 Identify novel CyPA receptors able to explain all of the
cellular events associated with CyPA.
 Design therapeutic agents with the capacity to block
specific functions of CyPA while leaving other functions
unaffected and without any effect on other CyP isoforms.
Cyclophilins (CyPs) are a family of ubiquitous proteins
evolutionarily well conserved and present in all prokaryotes
and eukaryotes.1 They have peptidyl prolyl isomerase activity,
which catalyzes the isomerization of peptide bonds from trans
form to cis form at proline residues and facilitates protein
folding.2 Human CyPs consist of 16 family members that are
structurally distinct. Among them, the most abundant member
is CyPA, which makes up B0.1–0.6% of the total cytosolic
proteins.1,3 CyPAwas initially purified from bovine thymocytes
and identified as the primary cytosolic binding protein of the
immunosuppressive drug cyclosporin A (CsA).4
CyPA is believed to have important roles in many biological
conditions including protein folding, trafficking, and T-cell
activation (Table 1).
Although CyPA is present intracellularly, it can be secreted
from cells in response to inflammatory stimuli such as
hypoxia, infection, and oxidative stress.21,24–26
The secreted form of CyPA may mediate intercellular
communication acting as an autocrine/paracrine factor. In
fact, it was shown that extracellular CyPA stimulates pro-
inflammatory signals in endothelial cells (EC) and vascular
smooth muscle cells (VSMC),21,26 and it is a nonmitogenic
survival-enhancing autocrine factor that contributes to mouse
embryonic stem cell growth.27 Further, extracellular CyPA has
a potent chemotactic effect on leukocytes, monocytes, and
lymphocytes.25,28 The chemotactic activity of CyPA is
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mediated, in part, through the activation of the ubiquitous Ig
like CD147 cell receptor.29
A growing body of evidence suggested its involvement in
key processes underling human pathologies. The objective of
this article is to review the current knowledge of CyPA
regarding its potential role in several human diseases in order
to offer novel therapeutic strategies.
CyPA and Cardiovascular Disease
Vascular remodeling. It has become clear that increases in
reactive oxygen species (ROS) and inflammation represent
key pathogenic mechanisms for vascular disease. For
example, ROS have been implicated in the pathogenesis of
neointima formation in part by promoting VSMC growth as
well as stimulating pro-inflammatory events.30 In light of the
major importance of CyPA in those aspect closely related to
vascular remodeling, we analyzed the response to complete
carotid ligation in wild-type (WT) mice, CyPA knockout
(CyPA / ) mice, and mice overexpressing CyPA specifi-
cally in VSMC (termed VSMC-Tg).22 Analysis of ligated
arteries revealed that the intimal area as well as medial and
adventitial thickening were significantly lower in CyPA /
mice and significantly enhanced in VSMC-Tg mice versus
WT mice. Interestingly, there was a significant decrease in
the recruitment of inflammatory cells in ligated arteries of
CyPA / mice and a significant increase in VSMC-Tg mice
(approximately twofold) compared with WT mice. In addition,
extracellular signal-regulated kinase 1/2 (ERK1/2) activation
and Ki67þ cells were consistently decreased in CyPA /
mice after carotid ligation. These data strengthen the link
between CyPA expression and VSMC proliferation and
suggest that VSMC-derived CyPA is important for the
recruitment of inflammatory cells.
Abdominal aortic aneurysm (AAA). Inflammation has long
been known to contribute to the pathogenesis of AAA. More
than a decade ago, it was shown that treatment with CsA
attenuated the formation of AAA in the rat model of elastase
infusion.31 The authors of that study pointed out that the
immunosuppressive effects of CsA would probably preclude
its use in patients with aneurysms. We have recently
demonstrated that deletion of CyPA in mice prevents the
formation of AAA in response to infusion of angiotensin II
(Ang II).32 Importantly, mice lacking CyPA were completely
protected against aortic rupture leading to sudden death.
Mechanistic studies revealed that deletion of CyPA reduces
aortic inflammation, oxidative stress, and matrix degradation
(Figure 1). In a series of experiments involving bone marrow
(BM) transplantation, as well as experiments in which CyPA
was selectively overexpressed in VSMC, we showed that
expression of CyPA in VSMC, rather than BM–derived cells,
is crucial to the development of AAA. Finally, to demonstrate
its relevance to human aneurysmal disease, we showed that
Ang II caused the release of CyPA and the activation of
metalloproteinase 2 (MMP-2) in VSMC derived from human
AAA.
Recently, Prins et al.33 found that benzo[a]pyrene potenti-
ates the pathogenesis of AAA by increasing CyPA expres-
sion. Furthermore, simvastatin-treated patients with AAA
exhibited lower CyPA mRNA, as well as CyPA intracellular
protein levels.34 Thus, the interference with signaling path-
ways leading to CyPA may reveal a new strategy in the
treatment of AAA.
Atherosclerosis. One of the major causes of AAA is
atherosclerosis, a disease characterized by chronic inflam-
mation of the arterial wall.35 Based on the premise that
atherosclerosis stimulates AAA, we hypothesized that CyPA
would necessarily have a significant impact on atherosclero-
sis development. We have characterized five important
pathological mechanisms by which CyPA promotes athero-
sclerosis (Figure 2).36 First, CyPA stimulates low-density
lipoprotein (LDL) uptake in the vessel wall by regulating the
expression of scavenger receptors. Second, CyPA increases
EC activation and inflammation by increasing vascular cell
Table 1 Major CyPA functions in protein folding and trafficking, T-cell activation and cell signaling
CyPA
functions
CyPA targets CyPA effects References
Folding HIV-1 Gag Promotion of both the formation and the infectivity of virions of HIV-1 5,6
Homo-oligomeric a7 neuronal nicotinic
receptor (nAChR) and type 3 serotonin
receptor (5HT3R)
Maturation of the homo-oligomeric receptor 7,8
Collagen Acceleration of the folding of the procollagen I 9
Transferrin Acceleration of an initial stage in transferrin folding 10
Drosophila rhodopsin Folding and stability of R1-6 rhodopsin by the NinaA-encoded protein
(an eye-specific CyP)
11,12
Trafficking Apoptosis-inducing factor (AIF) Co-translocation to the neuronal nuclei to induce cell death after cerebral
hypoxia-ischemia and ALS
13,14
Heterogeneous nuclear ribonucleoprotein
A2 (hnRNP A2)
CXCR4-mediated nuclear export of hnRNP A2, nuclear translocation of
ERK1/2, and chemotactic cell migration
15
CD147 Transport to the plasma membrane 16
Asialoglycoprotein receptor (ASGPR) Distribution of ASGPR between the plasma membrane and the endosomal
pool
17
Fructose-1,6-bisphosphatase (FBPase) Import of FBPase into intermediate transport vesicles for vacuole delivery 18
Zinc-finger protein 1 (Zpr1) Promotion of nuclear export 19
T-cell activation Interleukin-2 tyrosine kinase (Itk) Positive regulation of Th1 profile and inhibition of Th2 differentiation 20
Cell Signaling ERK1/2 Stimulation of VSMC growth 21,22
JNK, p38 kinase, and IkB, NF-kB,
E-selectin, and VCAM-1
Stimulation EC apoptosis and inflammation 23
CyPA and human disease
P Nigro et al
2
Cell Death and Disease
adhesion molecule 1 (VCAM-1) expression. Third, CyPA
decreases endothelial nitric oxide synthase (eNOS) expres-
sion through kruppel-like factor 2 (KLF2) transcriptional
repression in EC. Fourth, CyPA is a key determinant for
tumor necrosis factor alpha (TNF-a)-induced EC apoptosis.
Finally, CyPA stimulates recruitment of inflammatory cells
derived from the BM to the aortic wall.
Thus, CyPAmay have an important role in several stages of
atherosclerosis. This observation is also supported by recent
papers suggesting that CyPA is involved in the early phase of
atherosclerosis by regulating fatty streak formation,37 and
later phases by affecting plaque rupture32,38 and thrombosis
that complicate the disease.39,40
Based on the literature reported above, it is now clear that
CyPA is a crucial mediator of vascular remodeling, AAA, and
atherosclerosis, three diseases that share common pathways
(Figure 3).
Cardiac diseases. Inflammation triggered by oxidative
stress is the cause of many human cardiac diseases
including hypertrophy, myocardial ischemia, and coronary
artery disease.41 Considering the role of CyPA in inflamma-
tion and ROS generation, we studied CyPA functions in heart
disease. In particular, we evaluated the role of CyPA in Ang
II–induced cardiac hypertrophy.42 Interestingly, mice lacking
CyPA exhibited significantly less Ang II–induced cardiac
hypertrophy. Most importantly, we proved that CyPA is
required for Ang II–mediated cardiac hypertrophy by directly
potentiating ROS production, stimulating the proliferation and
migration of cardiac fibroblasts, and promoting cardiac
myocyte hypertrophy.
In addition, May and coworkers43 demonstrated that CyPA
is involved in myocardial ischemia and reperfusion injury.
Emerging data suggested that CyPA might be a valuable
marker for predicting the severity of acute coronary syn-
dromes. Yan et al.44 reported that serum CyPA concentration
in unstable angina and acute myocardial infarction subjects
are significantly higher than those in patients with stable
angina and controls.
This study was confirmed by Satoh et al.45 that found that
plasma levels of CyPA correlated with the anatomical severity
of stable coronary artery disease.
In summary, CyPA is a critical determinant of cardiac
hypertrophy, myocardial ischemia, and reperfusion injury and
may be a helpful biomarker of coronary artery disease.
CyPA and Diabetes
Recently, Ramachandran et al.46 presented evidence for a
significant role of CyPA in the pathogenesis of diabetes. They
performed a proteomic analysis of high glucose-primed
monocytes, and identified CyPA as a potential secretory
marker of inflammation in type 2 diabetes. Specifically, they
reported that CyPA expression is reduced in circulating
monocytes from patients with type 2 diabetes. In addition,
they found that the levels of CyPA in plasma samples of
patients with diabetes and coronary artery disease are higher
in comparison with plasma obtained from healthy volunteers.
These data suggested that CyPA secreted from monocytes
could be an important pro-inflammatory stimulus for vascular
inflammation in patients with diabetes.
CyPA and Viral Infection
CyPA and human immunodeficiency virus (HIV-1). CyPA
has been extensively studied from the gene to protein level
during HIV-1 infection. CyPA is encoded by the peptidyl prolyl
isomerase A (PPIA) gene, and regulatory PPIA polymorphisms
were found to be a component of genetic susceptibility to
HIV-1 infection or disease progression.47 In addition, analysis
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Figure 1 CyPA is involved in AAA formation. Ang II induces ROS formation; this
in turn determines the release of CyPA from VSMC. Extracellular CyPA contributes
to the recruitment of inflammatory cells in the aneurysm site and the activation of
MMPs that degrade the extracellular matrix. CyPA itself induces ROS formation by a
positive feedback loop
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Figure 2 CyPA contributes to atherosclerosis formation. As atherosclerosis
progresses, inflammation and ROS induce the release of CyPA from VSMC, EC and
macrophages. Intracellular CyPA, as well as extracellular CyPA, influence LDL
uptake by regulating the expression of scavenger receptors on the vessel wall. Also,
CyPA induces inflammation of EC by increasing adhesion molecule expression and
decreasing eNOS expression. In addition, CyPA increases the apoptosis of EC.
Finally, CyPA induces the recruitment of inflammatory cells in atherosclerotic lesions
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of sera from HIV-1-infected individuals has revealed higher
protein concentrations of CyPA (about fourfold) compared with
sera of healthy controls.48 Interestingly, HIV-1 replication was
decreased in human CD4þ T cells when CyPA was knocked
out.49 Molecular insights have revealed that CyPA can interact
with HIV capsid proteins (CA domain).5 Furthermore, CyPA
interacts with HIV accessory proteins, such as the viral protein
R (Vpr) and Nef to facilitate a step in the viral life cycle
between penetration and reverse transcription.50,51 Recently,
it has been reported that CyPA in dendritic cells could
recognize the newly synthesized HIV-1 CA domain and
subsequently prompt an interferon type I (IFN-I) response
through activation of IRF3.52 Therefore, packaging of host
CyPA into HIV particles is an important step in HIV
morphogenesis and essential for HIV replication.
CyPA and hepatitis virus. Similar to HIV-1, several lines of
evidence indicate that CyPA positively regulates the
replication of hepatitis C virus (HCV).53 Knockdown of
endogenous CyPA significantly hampered HCV RNA
replication and viral protein expression.54 Molecular studies
provided evidence that CyPA enhances the replication of
HCV by binding to the non-structural 5A (NS5A) and NS5B
protein of HCV.55
CyPA is also important for hepatitis B virus (HBV) infection.
Higher serum CyPA levels were detected in chronic hepatitis
B patients than in healthy individuals.56
Studies on molecular mechanisms regulating HBV replication
showed that CyPA interacts with the small surface proteins
(SHBs) of the HBV surface antigen (HBsAg).56 It was
hypothesized that CyPA binds to SHBs and is secreted along
with HBsAg particles.53 Thus, CyPA may function as a
cell-intrinsic sensor able to recognize HCV and HBV proteins
in order to promote viral infection and replication.
CyPA and influenza A virus. CyPA was found in the core
of the influenza virion57 and was upregulated upon infection
by avian H9N2 influenza virus in AGS cells (a human gastric
carcinoma cell line).58 Liu et al.59 revealed that overexpres-
sion of CyPA blocked influenza A virus replication, whereas
the depletion of endogenous CyPA resulted in enhanced
production of influenza A virus. Furthermore, CyPA was
found to interact with the matrix protein 1 (M1) affecting the
early stage of viral replication. Finally, CyPA was able to
restrict influenza virus replication through accelerating
degradation of the M1 protein.
CyPA and other viruses. It was reported that vaccinia virus
(VV) infection led to an impressive increase in CyPA stability
and CyPA is incorporated into the virus particle during
morphogenesis.60 In addition, CyPA was found to act as a
chaperone for the nucleocapsid protein of the vesicular
stomatitis virus (VSV).61
CyPA was also reported to regulate severe acute respira-
tory syndrome coronavirus (SARS-CoV) replication through
binding to the nucleocapsid protein and incorporation into
particles.62
Then, it was shown that CyPA is required for the host IFN-I
response in rotavirus (RV) infection of MA104 cells.63 Finally,
Keyes et al.64 demonstrated that CyPA expression is an
important factor in human cytomegalovirus (HCMV) infection
and reactivation.
In light of the major importance of CyPA in the regulation of
infectivity and replication of several viruses, it is worth
proposing CyPA as target for anti-viral therapy.
Protozoan Parasites
An emerging body of literature is reporting CyPA importance
in the growth of protozoan parasites affecting humans. It has
been suggested that the mammalian host cell CyPA seems to
be involved in the intracellular replication cycle of Leishmania
major parasites, as CyPA siRNA interference or CsA reduced
the parasite burden.65 Some of the small CyPs from
Plasmodium falciparum and Toxoplasma gondii (i.e.
TgCyP18) have shown similar inhibitory profiles as those
established for the human CyPA.66,67
The involvement of CyPA in protozoan parasite growth was
also supported by the fact that CsA has anti-parasitic activity
against a wide variety of parasites68 with the exception of
Leishmania.69
CyPA and Cancer
Upregulation of CyPA. There is now an established body
of knowledge about the role of CyPA in cancer. Indeed,
various reports have shown that CyPA is upregulated in
cancer and is a key determinant for malignant transformation
and metastasis.70,71
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Figure 3 CyPA effects on EC, VSMC and macrophages. CyPA is secreted in
response to ROS. Extracellular CyPA increases DNA synthesis and inhibits
apoptosis in VSMC. In contrast, CyPA stimulates EC apoptosis, stimulates the
expression of adhesion molecules including E-selectin and VCAM-1. Also,
extracellular CyPA induces a pro-inflammatory status in macrophages by
stimulating cytokines and chemokines production as well as inducing the activation
of MMP-9 and decreasing apoptosis. These effects induce inflammation, EC
dysfunction, neointimal formation thereby accelerating vascular remodeling, AAA
and atherosclerosis
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In small cell lung cancer, overexpressed CyPA stimulates
cancer cell growth, whereas CyPA knockdown slows down
cancer cell growth.70,72
CyPA is involved in diverse pathological processes of
cancer development. Specifically, it has been reported that
overexpressed CyPA in many cancers: (1) helps cancer
proliferation,73 (2) regulates cell cycle progression,74 (3)
blocks apoptosis,75 and (4) promotes cell migration/
invasion.76
Interestingly, CyPA expression is influenced by
chemotherapeutic agents. For example, treatment with
anti-cancer drugs such as 5-aza-2-deoxycytidine, celecoxib,
and 5-fluorouracil, decreases CyPA expression in cancer
cells.77–79 Moreover, CsA and sanglifehrin A (SfA), the two
immunosuppressive drugs that bind CyPA, increase the
chemotherapeutic effect of cisplatin in glioblastoma
multiforme.80
Transcriptional regulation of CyPA. Recently, upregula-
tion of CyPA in cancers was reported to be controlled by p53
and HIF1a (Figure 4), two critical transcription factors for
cancer development. It was shown that CyPA protein is
upregulated by p53-induced apoptotic conditions and CyPA
may also confer p53 stability through its PPIase activity.81
However, overexpressed CyPA inhibits hypoxia- and cisplatin-
induced cell death in a p53- independent manner. Further-
more, it was found that, under hypoxic conditions, CyPA,
whose promoter contains the hypoxia response element
(HRE) motif, can be induced by HIF1a.75 Thus, the regulatory
relations of CyPA with p53 and HIF1a may present a new
insight in understanding CyPA function during cancer
development.
Drug resistance. Choi et al.75 also found that CyPA
overexpression decreases cisplatin-induced cell death,
whereas CyPA knockdown lower cell survival rates. These
results suggested that CyPA overexpression may lead to
drug resistance, which results in a bad outcome of
chemotherapy. Subsequent oligo-microarray analysis by Yu
and collaborators82 revealed that CyPA can upregulate the
expression of many cytokine and drug resistance-related
genes including drug metabolism and drug transport-related
genes. Some of these genes, such as IL-6, multidrug
resistance-associated protein 2 (MRP2), MRP3, microsomal
glutathione S-transferase 1 (MGST1), and glutathione
transferase zeta 1 (GSTZ1), may contribute to drug
resistance.83 In addition, CyPA promoted the expression of
many ATP-binding cassette (ABC) transporters,82 which are
able to reduce cellular drug accumulation and consequently
induce drug resistance. It was also observed that liver cells
stably expressing CyPA (SK-Hep1-CyPA) show an
increased resistance for the anti-cancer drugs doxorubicin
and vincristine. Also, the accumulation of doxorubicin was
reduced in SK-Hep1-CyPA cells. These data suggest that the
elevated expression of CyPA may contribute to clinical
resistance to chemotherapy.
In vivo studies. A report on CyPA in non-small-cell lung
cancer revealed that CyPA knockdown has a significant
effect on tumor growth in vivo.72 Two non-small-cell lung
cancer cell lines, 5M2 and LC-103H, stably transfected with
pSUPER-CyPA RNAi were grown as xenografts in severe
combined immunodeficient (SCID) mice, and CyPA knock-
down cells yielded slower-growing tumors than the cells
transfected with scrambled RNAi. This effect was confirmed
by overexpressing CyPA in the small airway epithelial cell
line, S1LEK3. These cells resulted in faster growing
xenografts in SCID mice compared with cells transfected
with the empty vector. Large tumors were observed in the
CyPA-overexpressing group, whereas none was observed in
the vector group.72
Other interesting data by Li et al.73 revealed that intra-tumor
injection of Pgenesil-2-CypA-shRNA decreases tumor develop-
ment in nudemice. These data indicated that CyPA suppression
by shRNAcould significantly decrease tumor growth in vivo, with
no apparent toxicity at the dose used.
CyPA and Nervous System Degeneration
Alzheimer disease. A growing body of evidence suggests
oxidative stress involvement in neurodegenerative
diseases.84 In addition, many papers showed the
contribution of CyPA in oxidative stress mediated-
diseases.21,30,32 Recently Bell et al.85 reported the
involvement of CyPA in Alzheimer disease. In particular,
they showed that astrocyte-derived human ApoE4 leads to
an age-dependent progressive blood–brain barrier (BBB)
breakdown (Figure 5). This event is driven by CyPA that
initiates a pro-inflammatory pathway activating nuclear
factor kappa B (NF-kB) and MMP-9. The activation of this
pro-inflammatory pathway in brain capillary pericytes
determines the release of neurotoxic molecules from the
vessels, damaging neurons and affecting their synaptic
connections.
Another recent paper by Kayenda et al.86 illustrated that the
CD147 receptor, by interacting with CyPA, can influence
amyloid-b peptide levels, a protein that is central to
p53
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Apoptosis
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Figure 4 CyPA induces cancer growth. Apoptosis and hypoxia, through the
activation of p53 and HIF1a, upregulate CyPA expression. This in turn stabilizes p53
protein. CyPA is also secreted by cancer cells and promotes cancer growth,
metastasis and drug resistance. Anti-cancer drugs, such as DAC and 5-FU,
decrease CyPA expression and thus block cancer progression. However, CyPA
upregulation also decreases cisplatin-induced cell death suggesting that CyPA may
lead to drug resistance
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Alzheimer’s disease pathogenesis. Furthermore, it has
been shown that copper affects the secretion of CyPA.87
This mechanism is of particular relevance in the nervous
system regulation as copper dyshomeostasis is responsible
for the neurological symptoms observed in genetically
inherited copper-dependent disorders (i.e., Menkes’ and
Wilson’s diseases), as well as Alzheimer disease.
Amyotrophic lateral sclerosis (ALS). It has been reported
that mutations in Cu/Zn superoxide dismutase-1 (SOD1) can
cause familial ALS.88 SOD1 transgenic mice that have the
mutant human SOD1 (G93A) substitution are used as a
model for ALS. Proteomic analysis of spinal cord of the G93A
SOD1 mouse showed a variation in the isoform pattern of
CyPA.89 In addition, overexpressed WT CyPA, but not CyPA
with a rotamase active site point mutation, protected cells
expressing ALS-related mutant SOD from death.90 Mechanistic
insights revealed that CyPA is involved in motor
neuronal cell death in ALS model mice by interacting with
apoptosis-inducing factor (AIF).14 In particular, in the spinal
cords of G93A SOD1 mice, the expressions of CyPA and AIF
were detected in the motor neurons, and AIF co-translocated
to the motor neuronal nuclei with CyPA. Furthermore,
Basso et al.91 found that CyPA is significantly enriched in
the insoluble fraction of spinal cords of ALS patients, thus
may contribute to protein aggregate formation in ALS.
Finally, Nardo et al.92 identified CyPA as biomarker for ALS
in peripheral blood mononuclear cells and find an association
with disease progression.
CyPA and Rheumatoid Arthritis (RA)
Of interest, RA has been the first condition in which a secreted
form of CyPA has been demonstrated in extracellular fluids.
As shown by Billich et al.93, CyPA was increased in the
synovial fluids of RA patients compared with knee osteoar-
thritis patients. Won-Ha Lee and his colleagues94 extended
the findings on CyPA in RA by demonstrating that macro-
phages of the synovial lining layer constitute the major source
of CyPA. In addition, they showed that stimulation of
monocytes with CyPA results in increased production of
inflammatory cytokines. Yang et al.95 also suggested that in
RA, the CyPA-CD147 interaction might contribute to the
destruction of cartilage and bone by upregulating MMP-9
expression and adhesion of monocytes/macrophages to
extracellular matrix. Similarly, Wang et al.96 suggested that
CyPA significantly enhances the secretion of MMP-2 and
MMP-9, cell invasion, and inflammatory cytokines production
of monocytes.
Recently, it has been demonstrated that the increased
expression of CD147 on neutrophils in RA may be
responsible for CyPA-mediated neutrophil migration into the
joints, elevated MMPs secretion, and cell invasion of
synoviocytes.97
Further, it was reported that CyPA affects IL-8-directed
chemotaxis in neutrophils of RA patients.98
Altogether, these data are of interest because they tighten
the links between CyPA and key pathological mechanisms
of RA.
CyPA and Sepsis
After the discovery of CyPA as an extracellular mediator in
RA, the role of CyPA in other inflammatory diseases was
evaluated. In 1997, Tegeder et al.99 reported that CyPA
PPIase activity is significantly higher in patients with severe
sepsis than healthy subjects. In addition, elevated
PPIase activity was associated with high mortality. Then,
Dear et al.,100 by using a mouse model of sepsis based on
cecal ligation and puncture, found that CyPA increased in
abundance in the liver after sepsis. Moreover, Huang and
collaborators101 reported that CyPA expression is modulated
in peripheral lymphocytes from Pseudomonas aeruginosa-
induced sepsis101,102 and scalded rabbits caused by Staphy-
lococcus aureus invasion.103
Finally, a comparative proteome analysis was performed on
protein extracts from humanmonocyte THP-1 cells stimulated
with either Lipoteichoic acid (LTA) from Staphylococcus
aureus (aLTA) and from Lactobacillus plantarum LTA (pLTA).
Interestingly, CyPA expression was significantly changed by
aLTA- or pLTA stimulation.104
It is concluded that CyPA is a mediator in the patho-
physiology of sepsis and might acquire a diagnostic value.
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Figure 5 CyPA promotes neurodegeneration. ApoE2 and ApoE3 secreted by
astrocytes, but not ApoE4, stimulates the low-density lipoprotein receptor-related
protein 1 (LRP1) on pericytes. This event suppresses the pro-inflammatory pathway
orchestrated by CyPA that leads to NF-kB and MMP-9 activation. As a
consequence, the MMP-9-mediated degradation of tight junction and basement
membrane proteins that causes BBB breakdown and neuronal dysfunction is
inhibited
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CyPA and Asthma
Constant and collaborators,105 using a mouse model of
asthmatic inflammation, showed a correlation between
CyPA and asthma. In particular, they found that
(1) extracellular CyPA is elevated in the airways of asthmatic
mice; (2) CyPA induces CD147-dependent chemotaxis of
activated CD4þ T cells in vitro; (3) in vivo treatment with
anti-CD147 mAb significantly reduces the accumulation of
inflammatory cells in lung tissues; and (4) anti-CD147
treatment significantly reduces airway epithelial mucin
production and bronchial hyperactivity to methacholine
challenge.
Recently, Stemmy et al.,106 by using a newmurine model of
chronic allergic asthma, found elevated concentrations of
extracellular CyPA, but not classic chemokines, in the chronic
phase of asthma. Also, blocking the activity of CyPA reduced
the recruitment and persistence of leukocytes. Interestingly, it
was reported that CyPA is present in nasal wash samples of
asthmatic patients during the chronic phase of the disease
and its levels associate with clinical parameters of disease
severity.107
CyPA and Periodontitis
Recently Li et al.108 addressed the possible association of
CyPA with pathological inflammation and destruction of
periodontal tissues. They found that CyPA expression was
dramatically elevated in inflamed gingival tissues as
compared with healthy gingival tissues and co-localized in
infiltrating macrophages and lymphocytes, as well as
osteoclasts and osteoblasts in interradicular bone. As
reported for other inflammatory diseases, CyPA expression
correlated with MMP-1, MMP-2, and MMP-9 expression in
inflamed gingiva. The same authors also collected gingival
tissues and peripheral blood from patients with moderate to
severe periodontitis or from healthy donors.109 CyPA was
found to localize in the infiltrating cells and/or in the
extracellular matrix in the inflamed gingival connective
tissues. Also, CyPA was involved in the inflammatory
response of periodontal tissues through inducing the
chemotaxis of PBMCs/neutrophils and the secretion of
TNFa/IL-8.
These data suggest that CyPA is associated with the
inflammatory infiltration and alveolar bone destruction of
periodontitis.
CyPA and Aging
Another interesting aspect of CyPA functions is its correlation
with aging. Recently, Li et al.110 showed that the expression of
CyPA increased with aging in normal skin, regardless of
whether it was exposed or shaded. Similarly, it has been
discovered that the expression level of CyPA is upregulated in
the epidermis of aged people compared with younger
people.111 Further, CyPA expression was found significantly
higher in old rats than in the younger ones.112 In contrast,
proteomic analysis of dermal fibroblasts cultured in vitro from
human healthy subjects of different ages revealed that CyPA
was markedly reduced with age, consistent with the reduced
de novo synthesis of proteins and failure in performing
biologically active conformational changes frequently
observed during aging.113
CyPA Inhibitors and Their Pharmacological Use
As outlined above, CsA is a CyPA inhibitor and is themost well
studied and tightest binding CyPA ligand identified to date.4
CsA binds both extracellular and intracellular CyPA and
inhibits its PPIase activity. In particular, it inhibits the protein
phosphatase calcineurin and blocks the translocation of
nuclear factor from activated T cells (NF-AT) from the cytosol
to the nucleus, thus preventing the transcription of genes
encoding pro-inflammatory cytokines.114,115
Yurchenko et al.29 reported that CD147 interacts with
extracellular CyPA in a CsA-sensitive fashion. Others showed
that CsA blocks the folding of some proteins9,10 and
modulates protein trafficking in cells.16,116,117
More importantly, CsA was shown by Borel et al.118 to be a
potent and specific inhibitor of T-cell responses to alloanti-
gens. This discovery led to widespread clinical use of CsA as
an immunosuppressant, revolutionizing organ transplantation
in humans. However, multiple side effects were observed with
the long-term use of CsA in organ transplant recipients,
especially severe nephrotoxicity, which remains one of the
major obstacles for a broader use of the drug in the treatment
of inflammation and other immune disorders.119
Thus, compounds that selectively inhibit CyPA without
immunosuppressive effects are urgently required and might
be applicable to the therapy of human diseases. In this case,
treatment with isoenzyme specific inhibitors (1) would
probably elicit fewer side effects than a global CyP inhibitor
like CsA and (2) would not get dispersed into a cellular sink
when sequestered by other CyPs.
Recently, scientists have synthesized derivatives of CsA that
lack calcineurin-binding properties and thus do not exhibit
immunosuppressive effects. The anti-inflammatory effect of these
compounds is achieved because they directly block the pro-
inflammatory and chemotactic functions of extracellular CyPA.
A growing body of scientific evidence has indicated that
these non-immunosuppressive analogs of CsA may have
applications in multiple therapeutic areas. In particular, they
are among the most promising of the new anti-HCV agents
under development. For example, Alisporivir (Debio 025) is
the first-in-class CyPA inhibitor that recently initiated a phase
III trial. It binds to CyPA and shows additive anti-viral effect
with pegylated interferon-alpha (pIFN-a) in patients with
genotype 1 and 4 HCV.120
In addition, another derivative of CsA, NIM811, has been
shown to promise anti-inflammatory effects in different
experimental models associated with inflammatory response,
such as acute lung injury and arthritis.121,122
Another current challenge is to design therapeutic agents
with the capacity to block specific functions of CyPA, while
leaving other functions unaffected. In this context, a study
reported the development of a small molecule with the
capacity to specifically inhibit CyPA functions, without any
effect on other CyP isoforms.123
Recently, a potent CyPA inhibitor, MM218, which can
selectively inhibit the extracellular fraction of CyPA, has been
CyPA and human disease
P Nigro et al
7
Cell Death and Disease
synthesized.124 It appears to have a stronger anti-inflamma-
tory effect than CsA, as well as no detectable adverse effects
in an animal model of acute lung injury125 and myocardial
reperfusion injury.126
It is hoped that the discovery of these novel selective drugs
for CyPA might lead to a number of possible therapeutic
applications in inflammatory disease.
Conclusions and Perspectives
Based on current knowledge reviewed above, it is now clear
that CyPA has multi-functional properties. A number of
biological studies demonstrated that CyPA is involved in
various cellular functions including protein folding, trafficking,
assembly, immune-modulation, and cell signaling.127
In light of what is known about CyPA, it is believed that an
increase in CyPA expression contributes to pathological
conditions. In fact, CyPA / mice are protected from
vascular remodeling,22 aortic aneurysm,32 atherosclerosis,36
cardiac hypertrophy,42 and ischemia/reperfusion injury.43 In
addition, CyPA knockdown decreases tumor growth
in vivo72,73 and CyPA inhibitors are the most promising of
the new ant-HCV agents.120 Furthermore, several studies
suggested that high CyPA expression correlates with poor
outcome of patients with inflammatory diseases.92,107,128
It is important to underline that both the intracellular and
extracellular form of CyPA are involved in its pathogenic
actions. Specifically, we found that, under inflammatory
conditions, CyPA is secreted from cells and acts as an
autocrine and paracrine factor that exacerbates oxidative
stress and inflammation.22,32,42 However, extracellular CyPA
has been found to have a biphasic effect, by promoting cell
proliferation and migration at low doses and cytotoxic effects
at higher doses.129
The mechanism by which CyPA contributes to the devel-
opment of inflammatory diseases may involve a complex
interplay of proteins and pathways including the membrane
receptor for CyPA, CD147. However, it is worth mentioning
that a number of mechanistic details are still unknown and
await further studies. Indeed, to date CD147 has not been
proven unequivocally to mediate all of the cellular events
associated with CyPA. Thus, the identification of novel
receptors for CyPA would be essential for future translational
efforts aimed at targeting the CyPA pathway.
In conclusion, it is believed that the development of agents
that selectively inactivate CyPA or that block binding of CyPA
to its receptor could prove to be a fruitful approach to
forestalling several human diseases.
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